- Home
- PLRX vs ORIC Comparison
PLRX vs ORIC Comparison
Compare PLRX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | ORIC |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 973.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLRX | ORIC |
|---|---|---|
| Price | $1.23 | $9.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $3.79 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 1.9M | 1.3M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $3.90 |
| 52 Week High | $15.00 | $14.93 |
Technical Indicators
Market Signals| Indicator | PLRX | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 27.03 |
| Support Level | $1.17 | $10.45 |
| Resistance Level | $1.35 | $12.50 |
| Average True Range (ATR) | 0.12 | 0.70 |
| MACD | -0.02 | -0.19 |
| Stochastic Oscillator | 12.50 | 0.47 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.